Table of Contents

company-logo

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Clarus Therapeutics Dividend Announcement

• Clarus Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Clarus Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Clarus Therapeutics Dividend History

Clarus Therapeutics Dividend Yield

Clarus Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Clarus Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Clarus Therapeutics Financial Ratios

P/E ratio-0.00
PEG ratio-0.00
P/B ratio-0.00
ROE33.08%
Payout ratio0.00%
Current ratio0.78
Quick ratio0.57
Cash Ratio0.40

Clarus Therapeutics Dividend FAQ

Does Clarus Therapeutics stock pay dividends?
Clarus Therapeutics does not currently pay dividends to its shareholders.
Has Clarus Therapeutics ever paid a dividend?
No, Clarus Therapeutics has no a history of paying dividends to its shareholders. Clarus Therapeutics is not known for its dividend payments.
Why doesn't Clarus Therapeutics pay dividends?
There are several potential reasons why Clarus Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Clarus Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Clarus Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Clarus Therapeutics a dividend aristocrat?
Clarus Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Clarus Therapeutics a dividend king?
Clarus Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Clarus Therapeutics a dividend stock?
No, Clarus Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Clarus Therapeutics stocks?
To buy Clarus Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Clarus Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.